These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30293197)

  • 1. PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.
    Brumberg J; Tran-Gia J; Lapa C; Isaias IU; Samnick S
    Ann Nucl Med; 2019 Feb; 33(2):69-77. PubMed ID: 30293197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease.
    Doppler CEJ; Kinnerup MB; Brune C; Farrher E; Betts M; Fedorova TD; Schaldemose JL; Knudsen K; Ismail R; Seger AD; Hansen AK; Stær K; Fink GR; Brooks DJ; Nahimi A; Borghammer P; Sommerauer M
    Brain; 2021 Oct; 144(9):2732-2744. PubMed ID: 34196700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenergic Deficits in Parkinson Disease Imaged with
    Nahimi A; Sommerauer M; Kinnerup MB; Østergaard K; Winterdahl M; Jacobsen J; Schacht A; Johnsen B; Damholdt MF; Borghammer P; Gjedde A
    J Nucl Med; 2018 Apr; 59(4):659-664. PubMed ID: 28848039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.
    Ding YS; Singhal T; Planeta-Wilson B; Gallezot JD; Nabulsi N; Labaree D; Ropchan J; Henry S; Williams W; Carson RE; Neumeister A; Malison RT
    Synapse; 2010 Jan; 64(1):30-8. PubMed ID: 19728366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2.
    Arakawa R; Okumura M; Ito H; Seki C; Takahashi H; Takano H; Nakao R; Suzuki K; Okubo Y; Halldin C; Suhara T
    J Nucl Med; 2008 Aug; 49(8):1270-6. PubMed ID: 18632811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
    Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
    Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging human brown adipose tissue under room temperature conditions with (11)C-MRB, a selective norepinephrine transporter PET ligand.
    Hwang JJ; Yeckel CW; Gallezot JD; Aguiar RB; Ersahin D; Gao H; Kapinos M; Nabulsi N; Huang Y; Cheng D; Carson RE; Sherwin R; Ding YS
    Metabolism; 2015 Jun; 64(6):747-55. PubMed ID: 25798999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Quantification of the Norepinephrine Transporter in Human Brain with (
    Moriguchi S; Kimura Y; Ichise M; Arakawa R; Takano H; Seki C; Ikoma Y; Takahata K; Nagashima T; Yamada M; Mimura M; Suhara T
    J Nucl Med; 2017 Jul; 58(7):1140-1145. PubMed ID: 27980046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.
    Sommerauer M; Hansen AK; Parbo P; Fedorova TD; Knudsen K; Frederiksen Y; Nahimi A; Barbe MT; Brooks DJ; Borghammer P
    Mov Disord; 2018 Jul; 33(6):1006-1010. PubMed ID: 29797351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emotional eating and in vivo norepinephrine transporter availability in obesity: A [
    Bresch A; Rullmann M; Luthardt J; Becker GA; Reissig G; Patt M; Ding YS; Hilbert A; Sabri O; Hesse S
    Int J Eat Disord; 2017 Feb; 50(2):152-156. PubMed ID: 27611116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease.
    Nahimi A; Kinnerup MB; Sommerauer M; Gjedde A; Borghammer P
    Int Rev Neurobiol; 2018; 141():251-274. PubMed ID: 30314598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.
    Li CS; Potenza MN; Lee DE; Planeta B; Gallezot JD; Labaree D; Henry S; Nabulsi N; Sinha R; Ding YS; Carson RE; Neumeister A
    Neuroimage; 2014 Feb; 86():306-10. PubMed ID: 24121204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine.
    Ding YS; Lin KS; Logan J; Benveniste H; Carter P
    J Neurochem; 2005 Jul; 94(2):337-51. PubMed ID: 15998285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmental modeling of [(11)C]MENET binding to the norepinephrine transporter in the healthy human brain.
    Adhikarla V; Zeng F; Votaw JR; Goodman MM; Nye JA
    Nucl Med Biol; 2016 May; 43(5):318-23. PubMed ID: 27150035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of norepinephrine transporters.
    Ding YS; Lin KS; Logan J
    Curr Pharm Des; 2006; 12(30):3831-45. PubMed ID: 17073682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.